Welcome to our dedicated page for Optimi Health news (Ticker: OPTHF), a resource for investors and traders seeking the latest updates and insights on Optimi Health stock.
Optimi Health Corp. reports on its role as a commercial-stage pharmaceutical manufacturer of regulated botanical wellness drug products, including GMP-manufactured MDMA capsules and natural botanical research compound capsules. Company updates commonly cover Health Canada-licensed production, export permits, finished dosage forms, and supply into regulated medical access pathways.
Recurring news themes include shipments and clinical use under Australia’s Authorised Prescriber Scheme, products supplied for PTSD and treatment-resistant depression, access through Canada’s Special Access Program, and initiatives to expand manufacturing capability to ibogaine. Optimi also reports capital-market actions, financing documents, investor presentations, and regulatory readiness tied to its cross-border commercial strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.